Bayer AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William N. Anderson
- Full Time Employees
- 90,587
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Kaiser-Wilhelm-Allee 1 Leverkusen Germany 51368
- IPO Date
- Nov 18, 1996
- Website
- bayer.com
- Similar Companies
- Business
- Bayer AG is a global life science company headquartered in Leverkusen, Germany, primarily engaged in the healthcare and agriculture sectors. The company operates through three main segments: Pharmaceuticals, Consumer Health, and Crop Science. Its Pharmaceuticals segment develops, manufactures, and markets prescription medicines focusing on cardiology, oncology, hematology, ophthalmology, women's health, and specialized therapies including cell and gene therapies. The Consumer Health division offers over-the-counter products spanning nutritional supplements, allergy relief, cough and cold remedies, dermatology products, pain management, cardiovascular risk prevention, and digestive health. Bayer’s Crop Science unit provides products and services in crop protection, seeds and traits, digital farming, fruits and vegetables, and environmental science solutions aimed at sustainable agriculture. Bayer maintains a global footprint with operations across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Founded in 1863, Bayer continues to be a leader in pharmaceutical and agricultural innovation. In recent major developments during 2024 and 2025, Bayer has continued its corporate restructuring under the Dynamic Shared Ownership operating model introduced in early 2024, aiming to increase agility and operational efficiency. This has involved workforce reductions of approximately 12,000 jobs worldwide, focusing on management and administrative layers, with expected annual cost savings of up to 2 billion euros by 2026. Bayer has advanced a differentiated pharmaceutical pipeline targeting oncology, cardiovascular diseases, neurology, rare diseases, and immunology, with anticipated product launches including treatments for heart failure and hormone-free solutions for menopausal symptoms by the end of 2025. It also pursues growth in cell and gene therapy and targeted radiopharmaceuticals. On the Crop Science front, Bayer is rolling out innovations such as the Preceon Smart Corn System and new herbicides while focusing on digital farming and environmental sustainability. Despite pressure from investors to divest or break up its business units, Bayer has postponed any structural separation, instead emphasizing portfolio management and strategic alliances. The company also navigates significant legal provisions related to litigation over its Roundup weedkiller product. Overall, Bayer maintains a strong commitment to research and development to support its leadership in life sciences globally.
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
Bayer Says 'Not Now' To Monsanto Spin-Off Amid Ongoing Roundup Legal Battle
Bayer says no plans to restructure despite litigation threat
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
Bayer sued for allegedly monopolizing US market for GMO corn seeds
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer says FDA grants priority review designation for finerenone
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer Aktiengesellschaft Backs Crop Science Targets as Seed Pipeline Gains Momentum
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
Bayer Aktiengesellschaft (BAYRY) Q1 2026 Earnings Call Transcript